Cost-effectiveness of novel regimens for Chinese patients with chronic hepatitis C

References

• Yang S, Wu J, Ding C, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infect Dis 2017;17:716–25
   PubMed Web of Science ®Google Scholar
• Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017;14:122–32
   PubMed Web of Science ®Google Scholar
• Trembling PM, Tanwar S, Rosenberg WM, et al. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:713–28
   PubMed Web of Science ®Google Scholar
• Wei L, Zhang M, Xu M, et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol 2016;31:1860–7
   PubMed Web of Science ®Google Scholar
• Lim SG, Aghemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol 2017;2:52–62
   PubMed Web of Science ®Google Scholar
• Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014;29:545–53
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Chan HL, et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine 2016;95:e2702
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Z, Tobe RG, et al. Cost effectiveness of daclatasvir plus asunaprevir therapy for Chinese patients with chronic hepatitis C virus genotype 1b. Clin Drug Invest 2018;38:427–37.
   PubMed Web of Science ®Google Scholar
• Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations. China J Pharm Econ 2011;6:7–14.
   Google Scholar
• Ren Y, Liu M, Zhao J, et al. Serum vitamin D(3) does not correlate with liver fibrosis in chronic hepatitis C. World J Gastroenterol 2015;21:11152–9
   PubMed Web of Science ®Google Scholar
• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124–35
   PubMed Web of Science ®Google Scholar
• Marshall AD, Saeed S, Barrett L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 2016;4:E605–14
   PubMedGoogle Scholar
• Zhao SH, Chu YL, Cheng DX, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract 2009;63:1334–9
   PubMed Web of Science ®Google Scholar
• Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260–9
   PubMed Web of Science ®Google Scholar
• Ahmed H, Abushouk AI, Menshawy A, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig 2017;37:1009–23
   PubMed Web of Science ®Google Scholar
• Wang HL, Lu X, Yang X, et al. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:45–52
   PubMed Web of Science ®Google Scholar
• Zhu GQ, Zou ZL, Zheng JN, et al. Systematic review and network meta-analysis of randomized controlled trials: comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C genotype 1. Medicine 2016;95:e3004
   PubMed Web of Science ®Google Scholar
• Lai CL, Wong VW, Yuen MF, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther 2016;43:96–101
   PubMed Web of Science ®Google Scholar
• Fathi H, Clark A, Hill NR, et al. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. BMC Infect Dis 2017;17:722
   PubMed Web of Science ®Google Scholar
• Wong WW, Lee KM, Singh S, et al. Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open 2017;5:E97–108
   PubMedGoogle Scholar
• Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, et al. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. Daru 2017;25:11
   PubMed Web of Science ®Google Scholar
• Wang X, Liu F, Wei F, et al. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. PLoS One 2014;9:e100128
   PubMed Web of Science ®Google Scholar
• Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of HCV: results from a Phase 3b study in China. J Gastroenterol Hepatol 2018;33:1168–76
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418–31
   PubMed Web of Science ®Google Scholar
• Le AK, Zhao C, Hoang JK, et al. Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response. Aliment Pharmacol Ther 2017;46:605–16
   PubMed Web of Science ®Google Scholar
• Lee MH, Huang CF, Lai HC, et al. Clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis C patients. Sci Rep 2017;7:3718
   PubMed Web of Science ®Google Scholar
• Van Calster B, Vickers AJ. Calibration of risk prediction models: impact on decision-analytic performance. Med Decis Making 2015;35:162–9
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397–406
   PubMed Web of Science ®Google Scholar
• Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016;176:65–73
   PubMed Web of Science ®Google Scholar
• Chen GF, Wei L, Chen J, et al. Will sofosbuvir/ledipasvir (harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? An economic analysis using real-world data. PLoS One 2016;11:e155934
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396–405
   PubMed Web of Science ®Google Scholar
• Zhang H, Zheng J, Liu W, et al. Investigation and strategic analysis of public willingness and attitudes toward organ donation in East China. Transplant Proc 2015;47:2419–24
   PubMed Web of Science ®Google Scholar
• Halldorson J, Roberts JP. Decadal analysis of deceased organ donation in Spain and the United States linking an increased donation rate and the utilization of older donors. Liver Transpl 2013;19:981–6
   PubMed Web of Science ®Google Scholar
• Zheng R, Zuo T, Zeng H, et al. Mortality and survival analysis of liver cancer in China. Zhonghua Zhong Liu Za Zhi 2015;37:697–702
   PubMedGoogle Scholar
• Wu CH, Tian GS, Wang QH, et al. Clinical features and prognosis of decompensated hepatitis C virus related cirrhosis. Zhonghua Yi Xue Za Zhi 2008;88:516–19
   PubMedGoogle Scholar
• Wang H, Jiang W, Zhou Z, et al.. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Hepatobiliary Surg Nutr 2013;2:188–97
   PubMedGoogle Scholar
• Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407–19
   PubMed Web of Science ®Google Scholar
• Kapol N, Lochid-Amnuay S, Teerawattananon Y. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterol 2016;16:91
   PubMed Web of Science ®Google Scholar
• Wenhui M, Wen C, Lai W. Cost-effectiveness analysis of peg-interferon alpha-2a plus ribavirin vs conventional interferon plus ribavirin for the treatment of chronic hepatitis C in China. China J Pharm Econ 2012;7:6–14.
   Google Scholar
• Mingming Z, Fei L, Yidan XU, et al. Cost-minimization analysis of interferonα1b and interferonα2b in the treatment of chronic hepatitis C. China Pharm 2016;27:3175–6, 3177
   Google Scholar
• Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm 2013;19:438–47
   PubMed Web of Science ®Google Scholar
• Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010;13:592–600
   PubMed Web of Science ®Google Scholar
• Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One 2017;12:e175189
   PubMed Web of Science ®Google Scholar
• Thein HH, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005;100:643–51
   PubMed Web of Science ®Google Scholar
• Sandmann FG, Mostardt S, Lhachimi SK, et al. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds? Expert Rev Pharmacoecon Outcomes Res 2018;18:475–86
   PubMed Web of Science ®Google Scholar
• Goldhaber-Fiebert JD, Jalal HJ. Some health states are better than others: using health state rank order to improve probabilistic analyses. Med Decis Making 2016;36:927–40
   PubMed Web of Science ®Google Scholar
• Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol 2017;15:827–37
   PubMed Web of Science ®Google Scholar
• Li X, Chan NS, Tam AW, et al. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. Eur J Clin Microbiol Infect Dis 2017;36:1801–9
   PubMed Web of Science ®Google Scholar
• Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: a national multicenter cross-sectional survey in 56 hospitals. Medicine 2017;96:e7885
   PubMed Web of Science ®Google Scholar
• Igarashi A, Tang W, Cure S, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin 2017;33:1–10
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: an economic evaluation and budget impact analysis. PLoS One 2018;13:e193112
   Web of Science ®Google Scholar
• Cipriano LE, Goldhaber-Fiebert JD. Population health and cost-effectiveness implications of a "treat all" recommendation for HCV: a review of the model-based evidence. MDM Policy Pract 2018;3:852542150
   Google Scholar
• Ferreira VL, Tonin FS, Assis JN, et al. Efficacy of interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials. Clin Drug Investig 2017;37:635–46
   PubMed Web of Science ®Google Scholar